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Summary
Background: Acute coronary syndrome (ACS) encom-
passes ST-segment elevation myocardial infarction 
(STEMI), non-ST-segment myocardial infarction 
(NSTEMI) and unstable angina (UA). Although ini-
tially a syndrome with a poor prognosis, the advent of 
acute percutaneous coronary intervention (PCI), with 
novel stents and anticoagulation therapy, as well as 
the establishment of acute chest pain units, has to a 
great extent improved the outcome for patients with 
ACS. 
Objective: The aim of the present study was to as-
sess the 30-day outcome for patients with ACS admit-
ted to the University Hospital of Zurich, and to com-
pare the data, particularly for in-hospital death, with 
results from various other registries, such as the inter-
national Global Registry of Acute Coronary Events 
(GRACE).
Methods: Between 2007 and 2010, we included con-
secutive patients with a diagnosis of ACS, examined 
in-hospital death and major adverse cardiac events 
(MACE) at 30-days, and compared our results with the 
esteemed GRACE-Registry. 
Results: During these 4 years, 1,787 consecutive 
patients were diagnosed with ACS. Of these, 55.8% (n 
= 998) had STEMI, 35.3% (n = 631) NSTEMI and 8.8% 
(n = 158) UA. In contrast, in the 
GRACE, out of 11 543 patients 30% 
(n = 3419) had STEMI, 25% (n = 
2893) NSTEMI and 38% (n = 4397) 
UA. The in-hospital death rate in 
our study group was 5.7% with 
STEMI, 2.5% with NSTEMI and 
1.3% with UA (p = 0.001). Hospital 
case fatality rates for STEMI, 
NSTEMI and UA from the GRACE 
were 7%, 5% and 3%, respectively 
(p <0.01). At the University Hospital of Zurich, myocar-
dial infarction occurred in 1.6%, 0.5% and 1.3% of the 
STEMI, NSTEMI and UA groups, respectively (p = 
0.120), compared with 3% with STEMI and 2% with 
NSTEMI in the GRACE (data for UA not available). 
Cardiogenic shock was present in 8.7%, 5.4% and 0.6% 
(p <0.001) at the University Hospital of Zurich com-
pared with 7%, 5%, and 2% (p <0.01) in patients from 
the GRACE for STEMI, NSTEMI and UA, respectively. 
Kaplan-Meier survival analysis including MACE re-
vealed that patients with STEMI had the most unfa-
vourable outcome when compared with NSTEMI and 
UA (p = 0.018). 
Conclusions: Our results indicate that patients 
with ACS from the “real-world” Zurich registry show a 
higher rate of STEMI and yet lower event rates for ad-
verse cardiovascular complications and in-hospital 
death when compared with the GRACE, which may be 
explained by the high standard of healthcare at this in-
stitution and implementation of novel therapeutic 
strategies.
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Introduction
Acute coronary syndrome (ACS) constitutes a spec-
trum of clinical presentations such as ST-segment ele-
vation myocardial infarction (STEMI), non-ST-seg-
ment myocardial infarction (NSTEMI) and unstable 
angina (UA) [1]. ACS is most commonly caused by rup-
ture of a vulnerable atherosclerotic plaques [2], al-
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versity Hospital of Zurich and who underwent coro-
nary angiography. As at this institution thrombolysis 
has been abandoned and all ACS patients are referred 
for angiography, this represents the true ACS popula-
tion. All patients enrolled in this registry were at least 
18 years of age. The time period of the inclusion of pa-
tients in our registry covered three redefinitions of 
myocardial infarction [13, 14]. However, because of the 
retrospective nature of the study we used the current 
definition of myocardial infarction of 2012 [15]. Retro-
spectively, data were collected using KISIM
®
 (Klinik 
Informations System Innere Medizin), an in-hospital 
software system. The data included baseline character-
istics such as cardiovascular risk factors, patients’ car-
diovascular medication on admission and laboratory 
values. Coronary artery disease (CAD) was classified 
as single vessel or multivessel disease, and the culprit 
lesion was documented and categorised in the follow-
ing manner: left main artery, left ascending artery, cir-
cumflex artery, right coronary artery or bypass graft 
disease. Furthermore we recorded haemodynamic pa-
rameters such as blood pressure, heart rate, left ven-
tricular enddiastolic pressure and left ventricular ejec-
tion fraction. Data were retrospectively analysed as 
part of the quality control at the University Hospital of 
Zürich.
Short-term follow-up
The occurrence of MACE, including in-hospital death, 
revascularization, coronary artery bypass graft 
(CABG), nonfatal myocardial infarction, stent throm-
bosis, cardiogenic shock, stroke and septic shock, was 
assessed at the 30-day follow-up. ACS was defined as 
typical angina, elevated cardiac enzymes and/or typi-
cal ECG changes. Stroke was recorded after the case 
was reviewed independently by a neurologist and was 
defined as focal neurologic deficits lasting longer than 
24 hours with a clinically relevant lesion on brain im-
aging. The second endpoint included in-hospital death.
Statistical analysis
Baseline characteristics and outcomes for the three pa-
tient groups were summarised using frequency tables 
with count and proportion for each category, or mean 
with the standard deviation (SD) or standard error of 
the mean (SEM) as appropriate. Differences between 
groups were tested using Chi-square or Fisher’s exact 
test for nominal endpoints, or the Kruskal-Wallis tests 
for continuous endpoints. Survival analysis for the 
three groups STEMI, NSTEMI and UA at 30-day fol-
low-up was performed using the Kaplan Meier-Method 
for the combined endpoint of MACE. The curves were 
compared using the logrank-sum test. SPSS software 
(Chicago, Illinois; Version 20.0) was used for all statis-
tical analysis. A p-value <0.05 was considered as sig-
nificant. Data are shown as percentages. 
though ulceration, fissuring, erosion or dissection with 
intraluminal thrombus formation may also be in-
volved. All these presentations are referred to as myo-
cardial infarction (MI) type 1 according to the Euro-
pean Society of Cardiology classification by Thygessen 
et al. [3]. Advances in medical therapy, and large clini-
cal trials and the guidelines established in conse-
quence, have substantially improved the treatment of 
ACS over recent past decades. Nonetheless, ACS re-
mains the leading cause of morbidity and mortality 
worldwide and such cardiovascular disease accounts 
for 17.3 million deaths per year [4]. 
Attempts have been made to evaluate hospital 
management and clinical outcomes using registries in 
order to monitor and improve the quality of care [5]. It 
is noteworthy that, in spite of available guidelines [6] 
on the management of ACS, current practice differs be-
tween hospitals and countries; as a consequence, dif-
ferences in outcomes for patients with ACS between 
centres and countries have been noted [7]. Further-
more, although randomised clinical trials are the gold 
standard of evidence-based medicine, the patient pop-
ulation in clinical trials may not truly represent “real 
life” patients [8]. Indeed, Steg et al. found that ineligi-
ble patients in randomised controlled trials had the 
highest mortality, while eligible participants showed 
the lowest mortality [9]. Similarly, Bosch and col-
leagues reported that patients who were excluded from 
a randomised trial assessing the outcome of NSTEMI 
had a worse risk profile, more comorbidities and a 
nearly three-fold higher mortality rate compared with 
eligible patients [10]. Consequently, registries are of 
significant importance in outcome evaluation of ACS. 
The Global Registry of Acute Coronary Events 
(GRACE) is a prospective, multinational study of pa-
tients with ACS which was launched in 1999, and 
which currently includes 30 participating countries 
and over 100,000 patients [11, 12]. However, even in 
such registries, the real world may not be fully re-
flected, as patients with shock are often not included.
Here, we present the acute and short-term out-
come for all consecutive patients with ACS enrolled in 
the Zurich-Acute Coronary Syndrome Registry (Z-
ACS), within a 4-year period. Thus, this patient cohort 
truly represents the real-world population seen in an 
urban tertiary centre, including sudden-death survi-
vors and patients in cardiogenic shock. Furthermore, 
we compared in-hospital death and major adverse car-
diovascular events (MACE) at 30 days, as outcome 
measures of this single-centre registry with those of 
the international GRACE registry.
Methods
Data collection
From 2007 to 2010, we included consecutive patients 
who were admitted with a diagnosis of ACS to the Uni-
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with UA were also more likely to take statins (51.3%; n 
= 81) than those with NSTEMI (37.4%, n = 236) or 
STEMI (19.5%, n = 195) (p <0.001). All cardiovascular 
medications taken prior to admission are summarised 
in table 1. 
After admission, patients with STEMI were more 
frequently treated with vasopressors (11.0%, n = 110) 
compared with those with NSTEMI (4.9%, n = 31) or 
UA (1.3%, n = 2) (p <0.001), and were more often intu-
bated, resuscitated or treated with glycoprotein IIb/
Results
Baseline characteristics
A total of 1,787 patients were included in the Zurich-
Acute Coronary Syndromes Registry. Among them, 
55.8% (n = 998) had STEMI, 35.3% (n = 631) NSTEMI 
and 8.8% (n = 158) had UA. The baseline demographic 
and clinical characteristics are given in table 1. 
Patients with STEMI (mean age ± SD = 62.4 ± 12.5 
years) were younger than patients with NSTEMI (65.3 
± 12.2 years) and UA (64.3 ± 12.3 years) (p <0.001) (ta-
ble 1 and fig. 1), and had fewer cardiovascular risk fac-
tors than the patients with NSTEMI and UA. Only 
smoking was more prevalent in patients with STEMI. 
A significant difference in cardiovascular risk factors 
was observed for the three groups of ACS, except for 
obesity (p = 0.831) and a known family history for ACS 
(p = 0.053) (table 1).
Of note, patients with UA were pretreated more 
aggressively, with preventive medication such as aspi-
rin, beta-blockers and statins, compared to patients 
with NSTEMI and STEMI. The proportion of patients 
receiving aspirin was 59.5% (n = 94) in patients with 
UA, 43.9% (n = 277) in the NSTEMI group and 26.6% 
(n = 265) in the STEMI group (p <0.001). Similarly, 
pretreatment with beta-blockers was more common 
among patients with UA (43.7%; n = 69) when com-
pared with those with NSTEMI (35.2%, n = 222) or 
STEMI (20.0%, n = 200) (p <0.001). Finally, patients 
Table 1
Baseline demographic and clinical characteristics of the patients.
STEMI NSTEMI UA Total p-value
 998 (55.8%) 631 (35.3%) 158 (8.8%) 1787  
Male 766 (76.8%) 474 (75.1%) 118 (74.7%) 1358 (76.0%) 0.694
Age (yr; mean ± SD) 62.4 ± 12.5 65.3 ± 12.2 64.3 ± 12.3 63.6 ± 12.5 <0.001
Cardiovascular risk factors     
HTN 506 (50.7%) 367 (58.2%) 89 (56.3%) 962 (53.8%) 0.011
DM 145 (14.5%) 139 (22.0%) 32 (20.3%) 316 (17.7%) <0.001
Hyperlipidaemia 333 (33.4%) 266 (42.2%) 75 (47.5%) 674 (37.7%) <0.001
Current smoker 465 (46.6%) 230 (36.5%) 59 (37.3%) 754 (42.2%) <0.001
Obesity 204 (20.4%) 126 (20%) 35 (22.2%) 365 (20.4%) 0.831
FH 242 (24.2%) 152 (24.1%) 52 (32.9%) 446 (25.0%) 0.053
Medication on admission     
Aspirin 265 (26.6%) 277 (43.9%) 94 (59.5%) 636 (35.6%) <0.001
Clopidogrel 89 (8.9%) 141 (22.3%) 39 (24.7%) 269 (15.1%) <0.001
Statin 195 (19.5%) 236 (37.4%) 81 (51.3%) 512 (28.7%) <0.001
Beta-blocker 200 (20.0%) 222 (35.2%) 69 (43.7%) 491 (27.5%) <0.001
ACE inhibitor 117 (11.7%) 149 (23.6%) 36 (22.8%) 302 (16.9%) <0.001
Diuretic 120 (12.0%) 159 (25.2%) 44 (27.8%) 323 (18.1%) <0.001
ARBS 103 (10.3%) 81 (12.8%) 30 (19.0%) 214 (12.0%) 0.005
CCB 79 (7.9%) 65 (10.3%) 18 (11.4%) 162 (9.1%) 0.149
Warfarin 17 (1.7%) 30 (4.8%) 6 (3.8%) 53 (3.0%) 0.002
STEMI = ST-segment elevation myocardial infarction; NSTEMI = non-ST segment myocardial infarction; UA = unstable angina;  
HTN = hypertension; DM = diabetes mellitus; FH = known family history; ARBS = angiotensin-receptor blocking agents;  
CCB = calcium-channel blocker.
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Figure 1
Frequency of STEMI, NSTEMI and UA stratified by age group.
STEMI = ST-segment elevation myocardial infarction; NSTEMI = 
non-ST-segment myocardial infarction; UA = unstable angina.
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BNP) values on admission and peak values were 
higher in the NSTEMI group compared with the 
STEMI and UA patients (p <0.001). All laboratory val-
ues are shown in table 3.
Short-term follow-up
The in-hospital mortality rate was 5.7% (n = 57) in the 
STEMI group, 2.5% (n = 16) in the NSTEMI group and 
lowest at 1.3% (n = 2) with UA (p = 0.001, fig. 2).
Unplanned revascularisations after discharge 
were more common in patients with UA (5.7%, n = 9) 
than in those with NSTEMI (2.2%, n = 14) or STEMI 
(2.5%, n = 25) (p = 0.047). CABG was not different 
between the three groups (p-value not significant). 
No difference was found in re-infarction rates between 
the three groups (STEMI 1.6%, n = 16; NSTEMI 0.5%, 
n = 3; UA 1.3%; n = 2; p = 0.120). Stent thrombosis oc-
curred in 1.1% (n = 11) of the STEMI group, and 0.2% 
(n = 1) of the NSTEMI group and 0.6% (n = 1) with 
UA (p = 0.091). 
Cardiogenic shock was significantly more common 
in the STEMI group (8.7%, n = 87) than with NSTEMI 
(5.4%, n = 34) or UA (0.6%, n = 1) (p <0.001). Cardiac 
IIIa-inhibitors. In addition, an intra-aortic balloon 
pump was implanted substantially more often in 
STEMI patients (12.6%, n = 126) than in those with 
NSTEMI (8.1%, n = 51) or UA (2.5%, n = 4) (p <0.001). 
These findings were mirrored by the haemodynamic 
parameters: patients with STEMI exhibited the lowest 
systolic blood pressure (p <0.001) and highest heart 
rate (p = 0.001). This was in line with the clinical find-
ing that 13.9% (n = 139) of patients with STEMI were 
in an unstable condition, compared with only 6.8% (n = 
43) of the NSTEMI and 1.3% (n = 2) of the UA patients 
(p <0.001). Table 2 summarises the acute medication, 
emergency procedures, haemodynamic parameters 
and findings at coronary angiography.
Patients with STEMI exhibited the highest plasma 
total cholesterol levels (p = 0.017) and white blood cell 
counts on admission (p <0.001). C-reactive protein 
(CRP) on admission was highest in the NSTEMI group, 
whereas patients with STEMI had the highest peak 
values. Troponin, creatinine kinase (CK), CK-MB and 
plasma myoglobin levels were highest in the STEMI 
group, reflecting more extensive myocardial damage. 
N-terminales probrain natriuretic peptide (NT-pro-
Table 2
Acute medication, emergency procedures, haemodynamic parameters and findings at coronary angiography.
STEMI NSTEMI UA Total p-value
 998 (55.8%) 631 (35.3%) 158 (8.8%) 1787  
Acute medication     
Vasopressors 110 (11.0%) 31 (4.9%) 2 (1.3%) 143 (8.0%) <0.001
GP-IIb/IIIa 295 (29.6%) 89 (14.1%) 13 (8.2%) 397 (22.2%) <0.001
Emergency procedures     
Intubation 88 (8.8%) 36 (5.7%) 3 (1.9%) 127 (7.1%) 0.002
Resuscitation 117 (11.7%) 34 (5.4%) 5 (3.2%) 156 (8.7%) <0.001
IABP 126 (12.6%) 51 (8.1%) 4 (2.5%) 181 (10.1%) <0.001
Unstable 139 (13.9%) 43 (6.8%) 2 (1.3%) 184 (10.3%) <0.001
Vital signs on admission (mean ± SD)     
HR (beats per min.) 74.4 ± 15.6 73 ± 15.3 68.9 ± 12.9 73 ± 15.4 0.001
SBP (mm Hg) 124.4 ± 27.0 131.1 ± 27.2 136.6 ± 26.0 127.7 ± 27.3 <0.001
DBP (mm Hg) 71.6 ± 15.3 69.9 ± 15.2 69.9 ± 12.8 70.9 ± 15.1 0.076
Haemodynamic parameters (mean ±SD)     
LVEDP (mm Hg) 21 ± 8.8 19.2 ± 8.0 17.6 ± 8.0 20 ± 8.5 <0.001
EF (%) 51.2 ± 11.6 55.2 ± 12.0 59.3 ± 8.7 53.4 ± 11.8 <0.001
Location of the lesion     
LM 9 (0.9%) 15 (2.4%) 8 (5.1%) 32 (1.8%) <0.001
LAD 467 (46.8%) 262 (41.5%) 72 (45.6%) 801 (44.8%) 0.112
LCX 126 (12.6%) 177 (28.1%) 47 (29.7%) 350 (19.6%) <0.001
RCA 383 (38.4%) 151 (23.9%) 25 (15.8%) 559 (31.3%) <0.001
Graft 13 (1.3%) 26 (4.1%) 6 (3.8%) 45 (2.5%) 0.001
Coronary angiography findings     
Single-vessel disease 512 (51.3%) 238 (37.7%) 69 (43.7%) 819 (45.8%) <0.001
Multivessel disease 486 (48.7%) 391 (62.0%) 89 (56.3%) 966 (54.1%) <0.001
STEMI = ST-segment elevation myocardial infarction; NSTEMI = non-ST segment myocardial infarction; UA= unstable angina; IABP = 
intra-aortic balloon pump; HR = heart rate; SBP = systolic blood pressure; DP = diastolic blood pressure; LVEDP = left ventricular end- 
diastolic pressure; EF = ejection fraction; LM = left main artery; LAD = left anterior descending artery; LCX = left circumflex artery;  
RCA = right coronary artery.
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tamponade was rare and numerically more common in 
the STEMI group (0.6%, n = 6) but was not statistically 
different from the other groups (0.2% (n = 1) with 
NSTEMI and 0% (n = 0) with UA). For septic shock 
(p = 0.513) and stroke (p = 0.612), there was no statis-
tically significant difference between the three groups 
(fig. 3).
Table 3
Laboratory values (mean ± standard deviation).
STEMI NSTEMI UA Total p-value
  998 (55.8%) 631 (35.3%) 158 (8.8%) 1787  
Cholesterol    4.9 (± 0.05)    4.7 (± 0.07)    4.6 (± 0.14)    4.8 (± 0.04) 0.017
HDL    1.1 (± 0.02)    1.1 (± 0.02)    1.1 (± 0.05)    1.1 (± 0.01) 0.838
LDL    3.3 (± 0.06)    3.0 (± 0.07)    2.8 (± 0.15)    3.1 (± 0.04) 0.002
TG    1.4 (± 0.04)    1.5 (± 0.06)    1.5 (± 0.10)    1.4 (± 0.03) 0.014
CRP on admission   15.7 (± 1.25)   18.3 (± 1.66)    9.5 (± 2.04)     16 (± 0.93) <0.001
CRP maximum   60.8 (± 3.17)   58.7 (± 3.94)   33.1 (± 5.27)   57.7 (± 2.31) <0.001
WBC on admission   12.2 (± 0.15)   10.0 (± 0.16)    8.6 (± 0.25)   11.1 (± 0.11) <0.001
WBC maximum   13.7 (± 0.17)   11.5 (± 0.20)    9.9 (± 0.35)   12.6 (± 0.13) <0.001
CK on admission  926.5 (± 53.70)  445.6 (± 27.68)  167.0 (± 24.87)  693.7 (± 32.72) <0.001
CK maximum 2386.5 (± 86.96)  870.7 (± 51.43)  317.2 (± 45.20) 1680.8 (± 56.32) <0.001
CK-MB on admission  114.0 (± 5.53)   62.2 (± 3.84)   28.0 (± 2.88)   88.6 (± 3.50) <0.001
CK-MB maximum  235.7 (± 8.57)  100.1 (± 5.31)   45.1 (± 5.26)  172.1 (± 5.53) <0.001
Myoglobin on admission  745.7 0±(44.02)  257.6 (17.96)  163.6 (± 51.30)  532.2 (± 27.32) <0.001
Myoglobin maximum 1284.1 (± 71.71)  522.2 (± 56.98)  323.2 (± 89.04)  945.4 (± 47.37) <0.001
Troponin T on admission    2.0 (± 0.16)    0.9 (± 0.09)    0.2 (± 0.09)    1.5 (± 0.10) <0.001
Troponin T maximum    6.1 (± 0.27)    2.2 (± 0.15)    4.1 (± 3.49)    4.5 (± 0.35) <0.001
NT-proBNP on admission 1758.7 (± 183.06) 2535.5 (± 253.78) 1895.9 (± 571.62) 2027.9 (± 144.68) <0.001
NT-proBNP maximum 3370.5 (± 245.68) 3928.3 (± 376.26) 2210.7 (± 580.05) 3456.9 (± 196.65) <0.001
STEMI = ST-segment elevation myocardial infarction; NSTEMI = non-ST segment myocardial infarction; UA = unstable angina;  
HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides; CRP = c-reactive protein; WBC = white blood count;  
CK = creatinine-kinase; BNP = brain-natriuretic peptide.
Figure 2
In-hospital death rate for the total population of ACS and comparison 
between STEMI, NSTEMI and UA.
ACS = acute coronary syndrome; STEMI = ST-segment elevation 
myocardial infarction; NSTEMI = non-ST-segment myocardial infarc-
tion; UA = unstable angina.
At the 30-day follow-up, the rate of MACE was 
9.0% (n = 160) for the total study population. The prev-
alence of MACE was higher in the STEMI group 
(10.6%, n = 106) than with NSTEMI (6.7%, n = 42) or 
UA (7.6%, n = 12) (p = 0.020). Moreover, the Kaplan-
Meier survival analysis revealed that the outcomes of 
STEMI, NSTEMI and UA were indeed substantially 
different (logrank test p = 0.018), in particular for the 
first days; after approximately 13 days, the survival 
curves ran in parallel (fig. 4).
Discussion
Our results reveal that overall ACS patients enrolled 
in the Z-ACS registry had a lower 30-day MACE rate 
and in-hospital mortality compared with the estab-
lished international GRACE registry [5], which reflects 
the high quality of the management of this patient pop-
ulation in this tertiary centre.
Our in-hospital mortality rates for STEMI are com-
parable to the OPERA Registry and Swiss registry of 
acute coronary syndrome (4.6% and 4.8% for STEMI, 
respectively) [16, 17], but significantly lower than in 
the PL-ACS Registry Pilot Group, which revealed an 
in-hospital mortality rate of 11.6% for STEMI and 8.7% 
for NSTEMI [18]. We also noted that patients with 
NSTEMI or UA had a more favourable outcome than 
patients with STEMI, as frequently reported previ-
original article
Cardiovascular Medicine 2013;16(4):115–122 120
pital mortality, were most commonly pretreated with 
aspirin, statins and/or beta-blockers on admission. 
This suggests that when a plaque rupture occurs, pa-
tients pretreated with aspirin may develop a smaller 
clot that is less likely to occlude a major coronary ar-
tery, while statin pretreatment may lead to smaller 
cholesterol cores within the vulnerable lesion resulting 
in smaller cavities after rupture of a plaque. In line 
with the latter interpretation, total cholesterol and 
LDL values were significantly lower in patients with 
UA, as compared with STEMI and NSTEMI. Of note, 
optical coherence tomography (OCT) studies have 
shown that STEMI patients have larger cavities than 
those with NSTEMI [19]. A previously published study 
from the GRACE has also demonstrated that preven-
tive cardiovascular premedication can influence the 
type of ACS presentation [20] and therefore might 
modulate clinical outcome. 
Although difficult to assess in a registry setting, 
several factors may have contributed to the low compli-
cation rates in the Z-ACS registry, including optimal 
management of ACS patients in a high volume centre 
with experienced operators. Indeed, volume and opera-
tor experience markedly influence ACS outcome [21, 
22]. Furthermore, the Zurich metropolitan area is 
rather small and hospitals are easy to reach. The Zu-
rich area also has a very efficient ambulance system, 
which further contributes to short-time periods from 
symptom onset to treatment. Other factors that may 
have contributed are those that are patient-related, 
such as age, a major determinant of outcome in ACS 
[23, 24]. The Z-ACS patients were somewhat younger 
(mean age for STEMI 62 years, NSTEMI 65 years, UA 
64 years) than the GRACE population (STEMI 64 
years, NSTEMI 68 years, UA 66 years) [5]. Indeed, in 
the Z-ACS registry, patients with STEMI were younger, 
and in the age group below 55 years the rate of STEMI 
was 28.3%, whereas in the age group over 75 years, 
only 20.4% presented with STEMI. An increasing fre-
quency of patients with NSTEMI was observed with 
advanced age, while the frequency of UA was stable 
over the various age groups. These observations are 
very similar to the GRACE [5].
Our results are the more impressive because in 
most trials, and also registries, patients in very poor 
health with comorbidities and in particular those with 
cardiogenic shock are usually excluded, which obvi-
ously changes reported patient outcomes [25–27]). In 
the Z-ACS registry, 6.8% of the patients presented in 
cardiogenic shock, whereas in trials commonly less 
than 2% of patients exhibited cardiogenic shock. Of 
note, cardiogenic shock complicates myocardial infarc-
tion and accounts for 50%–60% of in-hospital mortality 
among all age groups [28]. In line with these data, ex-
clusion of patients with cardiogenic shock in the Z-ACS 
registry would have led to an overall in-hospital mor-
tality of only 1.4%. Similarly, the MACE rate would 
Figure 3
Distributation of complications including, revascularisation, CABG, myocardial 
infarction, stent thrombosis, cardiac shock, cardiac tamponade, stroke and septic 
shock between the three groups of ACS.
CABG = coronary artery bypass graft; ACS = acute coronary syndrome.
Figure 4
Kaplan Meier survival curves for 30-day MACE rate of the three groups 
of ACS (STEMI, NSTEMI and UA).
MACE = major adverse cardiac events; ACS = acute coronary syn-
drome; STEMI = ST-segment elevation myocardial infarction; NSTEMI = 
non-ST-segment myocardial infarction; UA = unstable angina.
ously. Indeed, the in-hospital mortality rates were 
5.7%, 2.5% and 1.3%), respectively (p = 0.001). Also, 
STEMI patients were more likely to require resuscita-
tion, vasopressors or intubation. This indicates that 
STEMI patients are a high-risk cohort for whom treat-
ment strategies still make a significant difference to 
outcome.
It remains still unclear why certain ACS patients 
present as STEMI and others as NSTEMI or UA. Inter-
estingly, patients with UA, who had the lowest in-hos-
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have been 4.7% under these conditions. Thus, real-
world registries reflect the real world only if all pa-
tients with cardiogenic shock or out-of hospital cardiac 
arrest are included in the analysis. Furthermore, met-
ropolitan areas with suboptimal ambulance systems 
may underestimate their true mortality in ACS as 
many patients may not reach the hospital in time. Be 
that as it may, our results again demonstrate that 
there is still room for improvement in the management 
of patients with cardiogenic shock, who represent a 
highest risk subset. These patients would benefit most 
from new treatment strategies.
It is important to note that our patient cohort only 
included patients from one tertiary care centre with a 
high quality medical service. However, the GRACE 
registry contains a total of 18 cluster sites in 14 coun-
tries including newly industrialised countries. Un-
doubtedly, healthcare disparities affect the infrastruc-
ture and lead to inferior outcomes, in this case pertain-
ing to cardiovascular disease. Switzerland has one of 
the best healthcare systems in the world, which trans-
lates into high-quality care, as demonstrated by the 
Deloitte Centre for Health Solutions 2010 survey 
“Health care consumers in Switzerland 2010”. For in-
stance, with the advent of drug-eluting stents (DES), 
studies have shown that patients with STEMI under-
going primary angioplasty have better long-term out-
comes for up to 4 years as compared with those receiv-
ing bare-metal stents. In this regard, it is of interest 
that in Switzerland, DES were utilised in 91% of all pa-
tients in 2007 [29]. A recent randomised trial of Swiss 
centres comparing biolimus-eluting and bare metal 
stents in patients with STEMI indeed showed that 
DES are associated with better outcome [27]. At our in-
stitution, the use of DES based quality report was be-
tween 2007 and 2010 above 80%. 
Furthermore, appropriate medical pretreatment 
may affect outcome. Indeed, a report published by 
Stauffer et al., using data from the Acute Myocardial 
Infarction Swiss-Plus (AMIS Plus) registry, found, as 
in a similar Austrian study [30], that patients pre-
treated with combination of clopidogrel and percutane-
ous coronary intervention (PCI) had significantly lower 
morbidity and mortality, which may not be the case in 
settings with limited access to resources [31]. 
One limitation of our single-centre study was the 
retrospective and observational nature. However, the 
allcomer design potentially minimised selection bias. 
In this regard, many prospective, randomised, con-
trolled trials do not enrol all consecutive patients ow-
ing to exclusion criteria or missing informed consent. 
Here we present a reliable, allcomer registry in which 
all in-hospital events were carefully reported. How-
ever, data on long-term follow-up are lacking and only 
limited information on medical assessments such as 
door-to-balloon time, percentage of TIMI flow and rate 
of multivessel PCIs was available.
In summary, registries can serve as effective tools 
for evaluating outcomes and clinical practice. They are 
able to demonstrate to what degree the highest stan-
dards of evidence-based care are used and what impact 
they have on outcome. Our results provide such an in-
sight and strongly suggest that outcome must particu-
larly be improved in patients with cardiogenic shock, 
who contribute the most to morbidity and mortality in 
ACS. Furthermore, they strongly suggest that preven-
tive medication with aspirin, stains and beta-blockers 
may protect from STEMI, the clinical presentation 
with the worst outcome. 
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